R. Al-khalidi

P2RX7 purinoceptor as a therapeutic target in Duchenne muscular dystrophy

R. Al-khalidi, Rasha Al-khalidi, 2017 .

Co-delivery of indoleamine 2,3-dioxygenase prevents loss of expression of an antigenic transgene in dystrophic mouse muscles

D. Nowis, D. Górecki, R. Al-khalidi, 2016, Gene Therapy.

P2X7 Purinoceptor Affects Ectopic Calcification of Dystrophic Muscles

D. Górecki, R. Al-khalidi, Robin M H Rumney, 2022, Frontiers in Pharmacology.

Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism

J. Ambati, C. Bruno, D. Górecki, 2018, Acta Neuropathologica Communications.

P2RX7 Purinoceptor: A Therapeutic Target for Ameliorating the Symptoms of Duchenne Muscular Dystrophy

A. Teti, D. Górecki, G. Tozzi, 2015, PLoS medicine.

Sustained activation of P2X7 induces MMP-2-evoked cleavage and functional purinoceptor inhibition

L. Galas, P. Chan, D. Górecki, 2018, Journal of molecular cell biology.

Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism

J. Ambati, C. Bruno, D. Górecki, 2018, Acta neuropathologica communications.

The extent of UMOD gene polymorphism and its level in type 2 diabetes patients

R. Al-khalidi, Hadeel Abdelelah Abdel Razaaq, I. A. Alwan, 2020 .